|
Chemical
Name:
Olanzapine Brand
Name:
Zyprexa Manufacturer:
Eli
Lilly Description:
It is believed that Olanzapine’s antipsychotic
activity is mediated through a combination of dopamine and serotonin antagonism. Indications
and Use: Indicated
for the management of the manifestations of psychotic disorders. Contraindications,
Warnings and Precautions:
The
potentially fatal symptom complex of Neuroleptic Malignant Syndrome (NMS) has
been reported in association with this class of drugs.
Signs of NMS include muscle rigidity, altered mental status, high fever,
increased blood pressure, increased heart rate and cardiac dysrhythmia.
Tardive Dyskinisia (TD) is a potentially irreversible, involuntary
movement that may develop. The highest prevalence of TD is in the elderly, particularly
women. This medication has central
nervous system effects; therefore, alcohol should be avoided.
There are no adequate and well-controlled trials with Olanzapine in
pregnant women. This drug should be
used during pregnancy only if the potential benefit justifies the potential risk
to the fetus. Women should not
breast feed while taking this medication because it is not known if it is
excreted in breast milk. Adverse
Reactions:
Possible common side effects may include somnolence, agitation, insomnia,
headache, nervousness, hostility, dizziness and rhinitis.
Other side effects may include weight gain, constipation, dry mouth,
hypotension, edema and extrapyramidal symptoms. Dosing
Range:
Initially 5 to 10mg per day before bedtime.
Antipsychotic efficacy was demonstrated at 10 to 15mg per day in clinical
trials. The safety of doses greater
than 20mg per day have not been evaluated. |
|
These pages are solely for public informational purposes. The information cannot be relied on to make diagnoses or prescribe treatment in any individual. Persons who require such services should consult with a licensed professional. Send mail to ropa@redoakpsychiatry.com with questions or comments about this web site.© 2000 Red Oak Psychiatry Associates, P.A. Updated
11/26/2007
|